Repligen Corporation

RGEN · NasdaqGS · Stock · Healthcare
$184.17
+3.35% today
Delayed price,

What Repligen does

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Key facts

Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$11.69B
P/E (ttm)
248.9
Forward P/E
69.0
Dividend yield
0.00%
Beta
1.08
Profit margin
5.3%
Employees
2,000
Headquarters
Waltham, MA, United States
Exchange
NasdaqGS

Performance

1 Month
+4.1%
3 Months
+25.1%
6 Months
+40.4%
1 Year
+20.7%
5 Years
-35.7%
$100.9952-week range$198.87
Biggest setback — last 12 months
-39.8%
24 Nov 2025 → 11 May 2026
Fell from $171.02 to $102.87 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+84.4%
11 May 2026 → 21 Sept 2026
Ran from $102.87 to $189.68 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$160.27 (-13.0%)$184.17$211.64 (+14.9%)
3 Months$144.76 (-21.4%)$184.17$234.31 (+27.2%)
6 Months$131.02 (-28.9%)$184.17$258.89 (+40.6%)
12 Months$113.78 (-38.2%)$184.17$298.11 (+61.9%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 48.2%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.